{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_names_stdName in Standardized Name (approximate match)
Status:
Withdrawn
Source:
Ganglioside GM1 [Germany]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ganglioside GM1 is a monosialo-glycosphingolipid belonging to the gangliotetrahexosyl series that abundant in neurons of all animal species and plays important roles in many cell physiological processes, including differentiation, memory control, cell signaling, neuronal protection, neuronal recovery, and apoptosis. Ganglioside GM1 in neurons helps to transfer information from the exterior to the interior of the cell, through specific recognition and binding of biologically active molecules (membrane receptors and ion channels), and has specific functions in nerve conduction and/or synaptic transmission. The mechanisms underlying the effects of Ganglioside GM1 remain unclear in many cases, but it appears that these effects are often due to specific interactions between Ganglioside GM1 and proteins involved in signaling processes, within Ganglioside GM1-enriched lipid rafts in the plasma membrane. Ganglioside GM1 is a major component of total ganglioside mixtures from mammalian brains, from which it can be extracted and purified in large amounts. Ganglioside GM1 was widely used in the past as a therapeutic drug for a wide variety of neurological disorders. Further studies have shown that Ganglioside GM1 has immunogenic properties and led to the production of antibodies that promoted peripheral neuropathies such as Guillain–Barré syndrome.
Status:
Withdrawn
Source:
Diethylaminoethoxyhexestrol [Japan]
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Diethylaminoethoxyhexestrol is a coronary dilating agent, approved for the treatment of angina in 1958 and marketed under tradename Coralgil. Diethylaminoethoxyhexestrol was withdrawn from the market because of drug-related phospholipidosis in liver, spleen and other tissues. Studies indicate that lipidosis is caused by the accumulation of the drug in lysosomes and inhibition of phospholipase A.
Status:
US Approved Rx
(2007)
Source:
ANDA065381
(2007)
Source URL:
First approved in 1991
Source:
CEFZIL by CORDEN PHARMA
Source URL:
Class:
MIXTURE
Targets:
Conditions:
Cefprozil is a 2nd generation cephalosporin that is FDA approved for the treatment of mild to moderate infections of upper respiratory tract, lower respiratory tract, and uncomplicated skin and skin-structure infections. Cefprozil, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Common adverse reactions include diarrhea, nausea, vomiting, dizziness, abdominal pain and vaginitis. Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. Concomitant administration of probenecid doubled the AUC for cefprozil.
Status:
Other
Class:
MIXTURE
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1990
Source:
M032
Source URL:
Class:
MIXTURE
alpha-Amyl cinnamaldehyde is a pale yellow liquid fragrance material with a floral smell used in allergenic testing.
Status:
Possibly Marketed Outside US
Source:
M020
(2015)
Source URL:
First approved in 2009
Source:
M032
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm071835.htm laxative:stimulant laxative sennosides a and b
Source URL:
First approved in 1998
Source:
21 CFR 334
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03700294: Phase 1 Interventional Terminated Advanced Solid Tumors
(2018)
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2024)
Source:
NDA218614
(2024)
Source URL:
First approved in 2024
Source:
NDA218614
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2023)
Source:
NDA215842
(2023)
Source URL:
First approved in 2023
Source:
NDA215842
Source URL:
Class:
NUCLEIC ACID